Repurposed Treatment · 9 min read · Updated March 2026

DCA (Dichloroacetate): The Cheap Drug That Reverses the Warburg Effect

A simple molecule that forces cancer cells to stop using their preferred energy pathway and die. Phase I data in brain tumors. It costs almost nothing and no one can patent it. But peripheral neuropathy limits what we can do with it.

🔶 Grade C: Early / Limited Human Data

The Bottom Line

DCA (dichloroacetate sodium) is a small, cheap molecule that targets the most fundamental metabolic abnormality in cancer: the Warburg effect. Most cancer cells rely on glycolysis (sugar fermentation) for energy even when oxygen is available, which also makes them resistant to apoptosis (programmed cell death). DCA inhibits pyruvate dehydrogenase kinase (PDK), forcing cancer cells back to normal mitochondrial metabolism, which restores their ability to die.

The mechanism is elegant and well-characterized. Phase I trials in glioblastoma (Michelakis et al., 2010) and advanced solid tumors (Dunbar et al., 2015) confirmed that DCA reaches tumors, reverses Warburg effect markers, and is tolerable at moderate doses. A case report documented complete response in non-Hodgkin's lymphoma after standard chemotherapy failed.

The limitation is peripheral neuropathy: dose-dependent nerve damage that causes tingling, numbness, and pain. This is reversible but restricts the dose and duration of treatment. Genetic variation in the GSTZ1 enzyme affects individual susceptibility.

The Warburg Effect (Why This Matters)

In 1924, Otto Warburg observed that cancer cells ferment glucose even when oxygen is available ("aerobic glycolysis"). This is now called the Warburg effect, and it's so consistent across cancer types that it's the basis of PET scans: the radioactive glucose tracer lights up wherever cancer cells are consuming abnormal amounts of sugar.

The Warburg effect isn't just a quirk. It appears to be functionally linked to cancer's resistance to death:

  • Cancer cells suppress mitochondrial oxidative phosphorylation
  • This hyperpolarizes the mitochondrial membrane
  • Hyperpolarized mitochondria cannot release cytochrome c (the signal that triggers apoptosis)
  • Result: cancer cells that refuse to die, even when damaged

DCA's mechanism directly addresses this chain. By reactivating pyruvate dehydrogenase, it pushes pyruvate into the mitochondria, restores oxidative phosphorylation, normalizes the membrane potential, and allows apoptosis to proceed.

How DCA Works

  • PDK inhibition: DCA inhibits all four isoforms of pyruvate dehydrogenase kinase, the enzyme that keeps pyruvate dehydrogenase (PDH) inactive. When PDK is inhibited, PDH is activated, pushing pyruvate into the Krebs cycle instead of being converted to lactate.
  • Mitochondrial depolarization: Restores normal mitochondrial membrane potential, enabling apoptosis.
  • Cancer stem cell targeting: Michelakis showed DCA activity against glioma cancer stem cells, which have particularly strong glycolytic dependence.
  • Selective toxicity: Normal cells already use oxidative phosphorylation, so DCA has minimal effect on them. Only cells with suppressed mitochondria (cancer cells) are significantly affected.
  • Radiosensitization: A 2021 study showed DCA can sensitize glioblastoma cells to radiation by reversing their metabolic resistance.

Human Clinical Data

Glioblastoma Study (Michelakis et al., 2010)

The landmark study. Five patients with glioblastoma multiforme (the deadliest brain tumor) were treated with oral DCA at 12.5 mg/kg twice daily:

  • Tumor samples showed evidence of Warburg effect reversal (mitochondrial depolarization normalized)
  • Apoptosis was induced in tumor tissue but not surrounding normal brain
  • Cancer stem cell fraction was reduced
  • Three patients showed radiological evidence of tumor regression
  • One patient had sustained clinical stability for 15+ months

Published in Science Translational Medicine. This confirmed the mechanism works in living human tumors, but the sample size (5 patients, no control group) prevents drawing efficacy conclusions.

Phase I Solid Tumors (Dunbar et al., 2015)

Dose-escalation study in adults with recurrent malignant brain tumors:

  • Established the maximum tolerated dose
  • Confirmed peripheral neuropathy as the dose-limiting toxicity
  • Identified GSTZ1 genotype as a predictor of DCA clearance and neuropathy risk
  • Pharmacokinetics characterized: DCA takes months to reach steady-state at potentially effective levels

Notable Case Reports

  • Complete response in non-Hodgkin's lymphoma (2012): A patient who progressed on rituximab-CHOP chemotherapy achieved complete response with DCA. Published in Journal of Bioenergetics and Biomembranes.
  • 15-year clinical review (2023): A comprehensive review in Medical Research Archives documented DCA-based metabolic therapy over 15 years of clinical use, with multiple case reports of sustained responses.

The Neuropathy Problem

DCA's main limitation is dose-dependent peripheral neuropathy:

  • Affects sensory nerves: tingling, numbness, pain in hands and feet
  • Typically reversible when DCA is stopped, but takes weeks to months to resolve
  • The GSTZ1 enzyme metabolizes DCA. Genetic variants (particularly GSTZ1*1A) result in slower clearance and higher risk of neuropathy at standard doses
  • This genetic variation means some patients tolerate DCA well while others develop neuropathy quickly
  • Limits long-term use and maximum dosing, which may restrict anticancer efficacy

Why DCA Hasn't Advanced Further

DCA is an industrial chemical that has been off-patent for decades. It costs pennies to manufacture. This creates the same structural problem that plagues all repurposed cancer drugs:

  • No company will fund a $50-100M Phase III trial for a compound they can't patent
  • The Michelakis lab funded their trial through donations and Canadian government grants
  • Academic funding for a Phase II/III trial has not materialized at scale
  • Self-prescribing communities have sprung up online, which ironically undermines the case for formal trials (regulators worry about patient safety)

Practical Information

  • Dose (from trials): 12.5 mg/kg twice daily orally
  • Administration: Dissolved in water, taken orally
  • Cost: Very low ($20-50/month from chemical suppliers)
  • Monitoring needed: Regular neurological assessment for neuropathy symptoms. GSTZ1 genotyping recommended before starting.
  • Time to effect: DCA accumulates slowly. Months may be needed to reach potentially effective serum levels.

Our Assessment

DCA has one of the most elegant mechanisms in cancer repurposing: it targets the Warburg effect, the metabolic foundation of most cancers. The Michelakis glioblastoma study confirmed the mechanism works in living human tumors. The case reports are tantalizing. But the evidence base remains thin: small Phase I studies, no randomized controlled trials, and a dose-limiting side effect that restricts what can be achieved clinically.

DCA is a reasonable candidate for further clinical investigation, particularly in combination with other treatments (it may sensitize tumors to chemotherapy and radiation). But it is not a proven cancer treatment, and the neuropathy risk means it should only be used with medical supervision and monitoring.

For patients interested in metabolic approaches to cancer, DCA represents one piece of a larger metabolic therapy framework that also includes fasting/caloric restriction, ketogenic diet, and exercise, all of which target the same metabolic vulnerabilities from different angles.

Sources

  • Michelakis ED, et al. Sci Transl Med 2010;2(31):31ra34: "Metabolic modulation of glioblastoma with dichloroacetate"
  • Dunbar EM, et al. Invest New Drugs 2014;32:452-464: Phase I trial of DCA in recurrent brain tumors springer.com
  • PMC4455946: Phase 1 trial of DCA in adults with malignant brain tumors pmc.ncbi.nlm.nih.gov
  • Michelakis ED, et al. Br J Cancer 2008;99:989-994: "DCA as a potential metabolic-targeting therapy for cancer" nature.com
  • J Bioenerg Biomembr 2012: Complete response in NHL with DCA springer.com
  • PMC6885244: "DCA and Cancer: An Overview towards Clinical Applications" pmc.ncbi.nlm.nih.gov
  • PMC11206832 (2024): "Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts" pmc.ncbi.nlm.nih.gov
  • Medical Research Archives 2023: "15 Year Evolution of DCA-Based Metabolic Cancer Therapy" esmed.org
  • MDPI Int J Mol Sci 2021;22(14):7265: DCA radiosensitization of glioblastoma mdpi.com

Related Research

Medical Disclaimer: This is a research review, not medical advice. DCA can cause peripheral neuropathy and should only be used under medical supervision with regular neurological monitoring. Always consult with qualified healthcare professionals.

How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →